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The occurrence of radiation-induced toxicity is a very 
complex process that is always modulated by the individual 
[2]; if two patients receive the “same dose distribution” they 
will likely have different reactions and possibly one will 
experience toxicity while the other not. The availability of 
individual information potentially characterizing the patient 
response, including the “omics” information, is highly 
valuable, especially in the “high-tech” era of image-
guided/adaptive IMRT in which organs are more efficiently 
spared: the better sparing reduces the incidence and severity 
of toxicities and, at the same time, enhances the impact of 
individual sensitivity factors. This point reinforces the need 
to create large data bases including individually assessed 
clinical, biological and genetic information, in addition to the 
individual dose distribution. As a consequence, the approach 
of quantitatively modelling dose-volume relationships is 
increasingly becoming “phenomenological” [3]: robust 
methods for (dosimetric and non-dosimetric) variable 
selection able to condense the information in “reliable”, 
friendly to use, predictive models is a major field of 
research: the adaptation of statistical methods for data-
mining and to avoid over-fitting is a pivotal point of the 
story.  
Although the potentials of large data bases and of data 
sharing platforms on toxicity modelling are clear [4], we 
should not forget that the creation of large data-bases is not 
the “aim” but is a (powerful) “tool”. The outcome of the 
process in terms of robustness and reliability of the models 
will not only depend on the “numbers” (a highly important 
component) but also (and maybe more importantly) on the 
“quality” of data. Differently from the “easy” score of the 
success of a therapy (survival, tumour control), toxicity is a 
much more complex issue that deserves specific attention 
and the careful collection of patient-reported and/or 
physician-reported information, often for years. Well 
assessed prospective observational studies focused on 
specific toxicities seem to be the best choice; secondary 
analyses of high-quality data coming from controlled trials 
are also very important although they may be limited in some 
cases by too homogenous protocols restricting the spread of 
the delivered dose distributions.  
At the end of the circle, the external validation of integrated 
dose-volume models is clearly a crucial component of the 
next year’s research [3]: testing the generalizability of dose-
volume models will be a major end-points. In addition, robust 
results from phenomenological models are expected to feed 
up mechanistic approaches in a sort of mutual synergy that 
can further corroborate our knowledge: these two 
components (mechanistic and phenomenological) will likely 
cooperate much more in the next future. Relevant 
developments are expected to impact the quantitative 
modelling of normal tissue effects also from the side of the 
dosimetry data. The robust, organ-planning-DVH approach to 
quantitatively describe the relationship between 
dose/volume and toxicities should be overcome/refined in 
many relevant situations by directly looking to the 3D dose 
distribution, integrating the spatial information lost when 
using “classical” surrogates like DVH/EUD. Relevant examples 
are: the direct measurement of dose-map dissimilarities 
between patients [5], the quantification of local (and organ) 
effects by imaging biomarkers [6], the interplay between the 
dose received by different organs, the impact of anatomy 
changes during therapy and their incorporation into normal 
tissue predictive models.  
Quantitative modelling of normal tissue effects is lively 
present in current century and seems to have a brilliant 
future in contributing to rapidly improve the way we treat 
our patients with the promise to continuously reduce 
toxicity.  
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Drawing on experience as a practicing GP with a special 
interest in communication skills and shared decision making, 
the work of The Health Foundation funded MAGIC (Making 
Good decisions in Collaboration) programme and most 
recently on a collaboration with a Danish Oncology Hospital, 
Dr Dave Tomson will explore recent developments in Shared 
Decision Making (SDM). Using experience and expertise from 
the delegates we will 
a) check out attitudes and beliefs about the need and 
rationale for putting SDM centre stage in patient interactions,  
b) look at a useful model of SDM both for personal clinical 
practice and for teaching other clinicians,  
c) explore some of the key skills needed and the key 
challenges in doing better SDM with a particular focus on 
oncology – the constant changing nature of the evidence 
base, individualised care in a guideline driven world, dealing 
with personal bias, unwarranted versus warranted variation 
in practice, the tyranny of time.  
d) share some ideas about possible solutions to these 
challenges and think about some of the steps needed to both 
develop personal practice and implement programmes of 
development within departments and across hospital systems 
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Although various effective anti-cancer treatments have 
become available over the last decades, therapy resistance 
remains the major cause of death of cancer patients. Striking 
examples are patients with tumors that are defective in DNA 
repair by homologous recombination (HR). Despite initial 
responses to cancer therapy, resistance of primary or 
disseminated tumors eventually emerges, which minimizes 
therapeutic options and greatly reduces survival. The 
molecular mechanisms underlying this therapy escape are 
often poorly understood.  
A clinically relevant mechanism for the defect in HR is a lack 
of function of BRCA1. This defect impairs error-free repair of 
DNA double-strand breaks (DSB) – a feature that can be 
exploited by the treatment with DSB-inducing agents. Using 
the K14cre,Brca1F/F,p53F/F (KB1P) genetically engineered 
mouse model for BRCA1-mutated breast cancer, we have 
shown the success of this strategy. Tumors are highly 
sensitive to DNA cross-linking agents, or to the inhibition of 
topoisomerase I/II and poly (ADP-ribose) polymerase (PARP) 
(reviewed by Rottenberg & Borst, 2012). Despite this 
sensitivity, tumors are not eradicated and eventually drug-
refractory tumors emerge. In several of the resistant tumors 
we found that the HR defect can be partially rescued by 
down-regulation or knock-out of additional repair factors, 
such as 53BP1 (Jaspers et al. 2013) or REV7 (Xu et al. 2015).  
Based on these observations we set out to investigate 
whether this type of HR restoration can also explain 
radiotherapy resistance. For this purpose, we treated mice 
carrying KB1P tumors with high-precision radiotherapy. We 
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observed that KB1P tumors were initially hypersensitive to 
fractionated local delivery of radiotherapy, but could not be 
eradicated: tumors relapsed and eventually acquired stable 
resistance. To investigate whether HR was restored in the 
resistant tumors, we studied 53BP1 and RAD51 irradiation-
induced foci formation. Surprisingly, while restoration of HR 
was prominently found in tumors that acquired resistance to 
PARP or topoisomerase I inhibition, we did not find it in 
radiotherapy resistant tumors. To investigate this discrepancy 
more closely, 53BP1 and related repair factors were knocked 
out in cell lines derived from the KB1P model using the 
CRISPR/Cas9 technology. Consistent with our in vivo data, 
clonogenic assays showed that the knock-out of 53BP1 
conferred strong resistance to PARP1 inhibition. Intriguingly, 
the lack of 53BP1 sensitized BRCA1-deficient cells to 
radiotherapy. An in vitro competition assay confirmed the 
selection to maintain a functional 53BP1 allele during 
radiotherapy treatment. Based on the KB1P model, we 
therefore hypothesize that resistance mechanisms that 
frequently occur in response to PARP1 inhibition sensitize 
cells to radiotherapy. These results, and their significance to 
human cells, are currently further validated in additional in 
vivo models including patient-derived tumors. 
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Introduction: Stereotactic (ablative) body radiotherapy 
(SBRT/SABR) has been successfully used in the treatment of 
metastatic lesions and could be considered as a “curative 
option” for some oligometastatic patients. Multiple studies 
have described significant local control in brain, lung and 
liver metastases of various primary cancers. Results suggest 
SBRT/SABR could be an effective treatment extending 
patients' life span.  
Study: For example in our retrospective study involved 90 
patients, designed to test potential effectiveness of SBRT in 
the treatment of oligometastases irrespective of primary 
Between July 2007 and June 2010, 90 patients were treated 
with robotic SBRT/SABR for hepatic or pulmonary metastatic 
lesions. A total of 113 liver and 26 lung metastatic lesions in 
52 men (58%) and 38 women (42%) were treated. Median 
follow-up was 17 months. Median age at treatment was 65 
years (range, 23-84 years). Primary cancers were 63 GI, three 
lung, eight breast, four melanoma, three neuro-endocrine 
tumors, and three sarcomas. Median diameter of the lesions 
was 28 mm (range, 7-110 mm) for liver and 12.5 mm (range, 
5-63.5 mm) for lung. Local control rates at 1 and 2 years 
were 84.5% and 66.1%, respectively. Two-year overall survival 
rate was 70% (95% CI: 55-81%). The 1 and 2-year disease-free 
survival rates were 27% (95% CI: 18-37%) and 10% (95% CI: 4-
20%), respectively. Median duration of disease-free survival 
was 6.7 months (95% CI: 5.1-9.5 months). Observed toxicities 
included grade 1-3 acute toxicities. One grade 3 and no grade 
4 toxicity were reported. High-dose SBRT/SABR for 
metastatic lesions is both feasible and effective with high 
local control rates.  
Discussion: In the last 4 years, some reports have described 
the so call abscopal effect described as “an action at a 
distance from the irradiated volume but within the same 
organism.” Abscopal effect may be more pronounced in 
response to ablative (> 10 Gy) rather than conventional 
dosage or fractionation schedules and has been reported 
mostly in renal cell carcinoma and in melanoma. The effect is 
attributed to activation of the systemic immune response by 
increase antigen presentation (neo antigens released after 
rapid cell necrosis) and enhanced immune response. These 
concepts may be of clinical value, improving outcomes by 
inducing systemic abscopal effects and potentially combined 
SBRT/SABR with immunotherapy or lymphocytes activating 
agents. Furthermore, these results have raised the question 
whether classic radiobiological modeling, and the linear-
quadratic (LQ) model, are appropriate for large doses per 
fraction with the possibility of such an additional biological 
effects resulting from endothelial cell damage, enhanced 
tumor immunity, or both. These concepts will be discussed at 
the time of presentation.  
Conclusion: SBRT/SABR treatment is well tolerated with low 
toxicity rates. It could represent an interesting treatment 
option for oligometastatic patients not amenable to surgery, 
even when patients had been pre-treated with 
chemotherapy. The biological models behind the observed 
clinical efficacy are currently scrutinized. New combined 
treatment may be driven from such promising results. 
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Optimal treatment of head and heck squamous cell 
carcinoma (HNSCC) patients requires well organized 
interdisciplinary coordination. Standard treatment of locally 
advanced HNSCC is chemoradiation or surgery followed by 
chemoradiation. Cisplatin containing chemotherapy remains 
standard of care in combination with concurrent 
radiotherapy. Neither neoadjuvant chemotherapy, nor 
treatments with targeted drugs have changed this standard, 
although some data suggest that cetuximab can be used as 
substitute for cisplatin especially in HPV/p16 positive 
disease. Combinations of cetuximab or other EGFR1 
antagonists with chemoradiation did not improve patient’s 
outcome, but added toxicity. Overall, attempts to improve 
clinical outcome in locally advanced HNSCC with targeted 
drugs and new cytostatic drugs have not been successful. The 
situation is different in locoregionally recurrent HNSCC not 
amenable for local treatment and in metastatic disease. In 
these patients, the addition of cetuximab to cisplatin and 
5FU resulted in a significant survival benefit and 
consequently is considered as standard of care.  
HPV/p16 positive HNSCC represents a distinct entity, which is 
more sensitive to radiotherapy and cytotoxic drugs. Several 
strategies testing deescalated treatments are being tested in 
randomized trials. However, deescalated is not yet 
recommended outside clinical trials.  
Neoadjuvant chemotherapy followed by radiotherapy +/- 
chemotherapy or cetuximab, and primary chemoradiation 
have been shown to allow for organ preservation especially in 
laryngeal cancer in the majority of patients without 
compromising overall survival. However, adequate selection 
of patients is critical to obtain organ preservation with good 
functional outcome.  
Recent technological developments in surgery and 
radiotherapy like transoral robotic surgery and radiotherapy 
using intensity modulated radiotherapy (IMRT), volumetric 
modulated arc therapy (VMAT), image guided radiotherapy 
(IGRT), and stereotactic body radiation therapy (SBRT) have 
been evaluated in cohort studies and a few randomized 
trials. These technologies are suitable for decreasing early 
and late toxicity and improvement of functional outcome, 
but have not been shown to improve locoregional control, 
disease free survival, and overall survival.  
The available data on the topics addressed above will be 
shown and discussed. 
 
 
 
 
